Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
9Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Galmed Pharmaceuticals Ltd. (GLMD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
28Total relationships
4Distinct source URLs
11High confidence
0.796Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Galmed Pharmaceuticals Ltd. Suppliers
Ticker
Name
Confidence
Evidence
THIRD-PARTY
THIRD-PARTY
90%
We purchase finished Aramchol from a third-party under a clinical supply agreement.
ation required for the sale and/or commercialization of the Licensed Technology Products, test protocols and final reports of any testing or studies with respect to the Licensed Technology Products. …
Reciprocal relationship from GALT graph: Reciprocal relationship from GLMD graph: ation required for the sale and/or commercialization of the Licensed Technology Products, test protocols and final re…
Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: , contract manufacturers must obtain regulatory approval of their manufacturing facilities, processes and quality sys…
, contract manufacturers must obtain regulatory approval of their manufacturing facilities, processes and quality systems. In addition, pharmaceutical manufacturing facilities are continuously subjec…
Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can…
cilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to…
Reciprocal relationship from PRGO graph: Reciprocal relationship from GLMD graph: cilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdi…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from GLMD graph: ation required for the sale and/or commercialization of the Licensed Technology Products, test protocols and final r…
SNYNF
Sanofi
72%
ation required for the sale and/or commercialization of the Licensed Technology Products, test protocols and final reports of any testing or studies with respect to the Licensed Technology Products. …
Galmed Pharmaceuticals Ltd. Customers
Ticker
Name
Confidence
Evidence
SAMIL-PHARM-CO-LTD
SAMIL-PHARM-CO-LTD
85%
roduct sales to date, although we have historically generated revenue from our licensing agreement with Samil Pharm. Co., Ltd., or Samil. We have incurred operating losses in each year since the ince…
Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from GILD g…
, contract manufacturers must obtain regulatory approval of their manufacturing facilities, processes and quality systems. In addition, pharmaceutical manufacturing facilities are continuously subjec…
Reciprocal relationship from JNJ graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GLMD graph: incurred substantial losses since our…
incurred substantial losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $210.8 million and positive working capital (current assets less current liabi…
Reciprocal relationship from MTVA graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from MTVA g…
Reciprocal relationship from VKTX graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GLMD graph: Reciprocal relationship from VKTX g…
GALTOPA-THERAPEUTICS-LTD
GALTOPA-THERAPEUTICS-LTD
62%
. The Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development Ltd. (“GRD”) and Galtopa Therapeutics Ltd., both of…
NOVO-NORDISK-INC-MADRIGAL-PHARMACEUTICALS-INC
NOVO-NORDISK-INC-MADRIGAL-PHARMACEUTICALS-INC
62%
cial condition could be adversely affected. Before an NDA is approved, and before we begin the commercial manufacture of any product candidate, contract manufacturers must register with the FDA, MHRA…
Galmed Pharmaceuticals Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
GLMD-DEBT-9800
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2015-12-31.
Galmed Pharmaceuticals Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Galmed Pharmaceuticals Ltd..
Galmed Pharmaceuticals Ltd. Ownership
Holder
Name
Confidence
Evidence
GLMD-OWNER-JANE-STREET-GROUP-LLC
Jane Street Group, LLC
95%
13F/ownership overlay lists Jane Street Group, LLC; shares held 12,135; ownership 0.18%; value $7,552; as of 2025-12-31.
GLMD-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 1,814; ownership 0.03%; value $1,129; as of 2025-12-31.
GLMD-OWNER-XTX-TOPCO-LTD
Xtx Topco Ltd
95%
13F/ownership overlay lists Xtx Topco Ltd; shares held 11,048; ownership 0.17%; value $6,876; as of 2025-12-31.
GLMD-OWNER-BNP-PARIBAS-FINANCIAL-MARKETS
BNP Paribas Financial Markets
95%
13F/ownership overlay lists BNP Paribas Financial Markets; shares held 900; ownership 0.01%; value $560; as of 2025-12-31.
GLMD-OWNER-TSFG-LLC
Tsfg, Llc
95%
13F/ownership overlay lists Tsfg, Llc; shares held 17; value $10; as of 2025-12-31.
GLMD-OWNER-CITADEL-ADVISORS-LLC
Citadel Advisors Llc
95%
13F/ownership overlay lists Citadel Advisors Llc; shares held 38,177; ownership 0.58%; value $23,761; as of 2025-12-31.
GLMD-OWNER-MORGAN-STANLEY
Morgan Stanley
95%
13F/ownership overlay lists Morgan Stanley; shares held 298; value $185; as of 2025-12-31.
GLMD-OWNER-TWO-SIGMA-INVESTMENTS-LP
Two Sigma Investments, LP
95%
13F/ownership overlay lists Two Sigma Investments, LP; shares held 112,147; ownership 1.70%; value $69,800; as of 2025-12-31.
